Ticagrelor

Ticagrelor is an antiplatelet agent. Ticagrelor co-administered with acetylsalicylic acid (ACA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history myocardial infarction (MI) and a high risk of developing an atherothrombotic event.

IUPAC name: (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Trade name: Brilinta, Brilique
Other name: AZD-6140

BP2020